601607 On Other Exchanges
Symbol
Exchange
601607 is not on other exchanges.

shanghai pharmaceuticals-a (601607) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI PHARMACEUTICALS-A (601607)

Related News

No related news articles were found.

shanghai pharmaceuticals-a (601607) Related Businessweek News

No Related Businessweek News Found

shanghai pharmaceuticals-a (601607) Details

Shanghai Pharmaceuticals Holding Co., Ltd., together with its subsidiaries, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People’s Republic of China. It operates through Production, Distribution, Retail, and Others segments. The company offers a range of products, including chemical and bio-pharms, modern Chinese medicine, healthcare products, medical devices etc. in various therapeutic areas, such as cardiovascular, systemic anti-infections, digestive system and immune-metabolism, neuropsychiatric, and antineoplastic, as well as anti-tumor and immunomodulatory, musculo-skeletal, respiratory, genito-urinary and sex hormone, blood and blood-forming organ, neurological, and other therapeutic areas. It provides its products in various dosage forms that include tablets, capsules, powder, mini-volume injections, eye-drops, inhalants, coagulants etc. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it operates a network of retail pharmacy stores, as well as engages in consulting service, assets management, investment holding operations etc. Further, the company manufactures and trades medicines and medical equipment; and rents properties, as well as wholesales chemicals and active pharmaceutical ingredients. As of December 31, 2015, it had 1,769 chain retail pharmacies under its brand family, including 1,167 directly operated pharmacies. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China.

41,173 Employees
Last Reported Date: 03/18/16
Founded in 1994

shanghai pharmaceuticals-a (601607) Top Compensated Officers

President, Executive Director and Convener of...
Total Annual Compensation: CNY2.0M
Vice President
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

shanghai pharmaceuticals-a (601607) Key Developments

Shanghai Pharmaceuticals Holding Co., Ltd. Announces Management Appointments; Approves Cash Dividend for the Year 2015, Payable on 26 August, 2016

Shanghai Pharmaceuticals Holding Co., Ltd. announced at the AGM held on 28 June 2016 has approved the election of Zuo Min as executive director, Yin Jintao and Xie Zuchi as independent non-executive directors. The company has approved a cash dividend of CNY 3.30 per 10 shares (tax included) for the year 2015 to holders of H Shares whose names appear on the register of members of the company on 18 July, 2016. Relevant cheques will be despatched by the company's H share registrar, Computershare Hong Kong Investor Services Limited, on 30 August, 2016, to holders of H Shares entitled to receive such dividends. The Board notifies the shareholders and potential investors of the company that the payment date for the cash dividend for year 2015 will be changed to 26 August 2016 (instead of 30 August, 2016).

Shanghai Pharmaceuticals Holding Co., Ltd. Announces Management Changes

Shanghai Pharmaceuticals Holding Co., Ltd. announced the personnel changes in relation to the Board, the board of supervisors and management of the Company. Mr. ZHOU Jie, an executive director, has been elected by the Board as the chairman of the sixth session of the Board for a term for three years, with effect from 28 June 2016. Mr. XU Youli, a supervisor, has been elected by the board of supervisors as the chief supervisor of the sixth session of the board of supervisors for a term for three years, with effect from 28 June 2016. Mr. CHO Man, an executive director, has been elected by the Board as the convener of the Strategy Committee of the Board; Mr. TSE Cho Che, Edward, an independent non-executive director, and Mr. CAI Jiangnan, an independent non-executive director, have been elected by the Board as members of the Strategy Committee of the Board. Mr. TSE Cho Che, Edward, an independent non-executive director, has been elected by the Board as the convener of the Nomination Committee of the Board; Mr. ZHOU Jie, an executive director, and Mr. HONG Liang, an independent non-executive director, have been elected by the Board as members of the Nomination Committee of the Board. Mr. WAN Kam To, an independent non-executive director, has been elected by the Board as the convener of the Audit Committee of the Board; Mr. TSE Cho Che, Edward, an independent non-executive director, and Mr. HONG Liang, an independent non-executive director, have been elected by the Board as members of the Audit Committee of the Board. Mr. HONG Liang, an independent non-executive director, has been elected by the Board as the convener of the Remuneration and Assessment Committee of the Board; Mr. WAN Kam To, an independent non-executive director, and Mr. CAI Jiangnan, an independent non-executive director, have been elected by the Board as members of the Remuneration and Assessment Committee of the Board. Mr. CHO Man, an executive director, has been appointed as the president of the Company by the Board for the same term as the sixth session of the Board, with effect from 28 June 2016; and Mr. LIU Yanjun, Mr. REN Jian, Mr. SHU Chang and Mr. MAO Jianyi have been appointed as the vice presidents of the Company, Mr. SHEN Bo has been appointed as the chief financial officer of the Company, and Mr. LIU Dawei has been appointed as the Board secretary and the joint company secretary by the Board, all for the same term as the sixth session of the Board, with effect from 28 June 2016.

Shanghai Pharmaceuticals Holding Co., Ltd. Approves Amendments to the Articles of Association

Shanghai Pharmaceuticals Holding Co., Ltd. at its AGM held on June 28, 2016, approved Amendments to the Articles of Association.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

601607 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 601607.
View Industry Companies
 

Industry Analysis

601607

Industry Average

Valuation 601607 Industry Range
Price/Earnings 16.7x
Price/Sales 0.5x
Price/Book 1.6x
Price/Cash Flow 12.0x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SHANGHAI PHARMACEUTICALS-A, please visit www.pharm-sh.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.